Get the Stockscreener App
139.94
1.19%
-1.68
After Hours:
140.00
0.06
+0.04%
Biogen Inc stock is traded at $139.94, with a volume of 1.53M.
It is down -1.19% in the last 24 hours and up +5.85% over the past month.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
See More
Previous Close:
$141.62
Open:
$141.78
24h Volume:
1.53M
Relative Volume:
1.07
Market Cap:
$20.52B
Revenue:
$9.61B
Net Income/Loss:
$1.53B
P/E Ratio:
13.38
EPS:
10.46
Net Cash Flow:
$1.85B
1W Performance:
+5.50%
1M Performance:
+5.85%
6M Performance:
-1.90%
1Y Performance:
-31.72%
1-Day Range:
$137.14
$142.28
1-Week Range:
$131.52
$145.27
52-Week Range:
$110.03
$205.19
Biogen Inc Stock (BIIB) Company Profile
Name
Biogen Inc
Sector
Industry
Phone
(781) 464-2000
Address
225 BINNEY STREET, CAMBRIDGE, MA
Compare BIIB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BIIB
Biogen Inc
|
139.94 | 20.47B | 9.61B | 1.53B | 1.85B | 10.46 |
|
LLY
Lilly Eli Co
|
742.91 | 659.07B | 53.26B | 13.80B | -50.20M | 15.30 |
|
JNJ
Johnson Johnson
|
178.76 | 428.83B | 90.62B | 22.66B | 18.18B | 9.35 |
|
ABBV
Abbvie Inc
|
213.00 | 374.37B | 58.33B | 3.73B | 18.24B | 2.10 |
|
NVS
Novartis Ag Adr
|
128.42 | 245.16B | 53.40B | 13.68B | 16.89B | 6.9231 |
|
MRK
Merck Co Inc
|
84.05 | 213.51B | 63.43B | 16.42B | 14.72B | 6.49 |
Biogen Inc Stock (BIIB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-21-25 | Resumed | Truist | Hold |
| Apr-28-25 | Downgrade | HSBC Securities | Buy → Hold |
| Apr-04-25 | Downgrade | Argus | Buy → Hold |
| Feb-11-25 | Initiated | Bernstein | Mkt Perform |
| Jan-02-25 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-20-24 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Dec-16-24 | Downgrade | Stifel | Buy → Hold |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Dec-09-24 | Downgrade | Jefferies | Buy → Hold |
| Nov-18-24 | Downgrade | Needham | Buy → Hold |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Oct-31-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-10-24 | Resumed | Raymond James | Mkt Perform |
| Feb-14-24 | Reiterated | Needham | Buy |
| Feb-14-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-24-24 | Downgrade | UBS | Buy → Neutral |
| Dec-20-23 | Resumed | Cantor Fitzgerald | Overweight |
| Dec-07-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Sep-06-23 | Initiated | HSBC Securities | Buy |
| Jul-27-23 | Initiated | Scotiabank | Sector Outperform |
| Jul-24-23 | Reiterated | UBS | Buy |
| May-01-23 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-17-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Oct-26-22 | Upgrade | Goldman | Neutral → Buy |
| Oct-13-22 | Upgrade | Stifel | Hold → Buy |
| Oct-07-22 | Upgrade | Argus | Hold → Buy |
| Sep-28-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Sep-28-22 | Upgrade | Mizuho | Neutral → Buy |
| Sep-28-22 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Apr-18-22 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-08-22 | Downgrade | Stifel | Buy → Hold |
| Mar-03-22 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Feb-04-22 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Feb-04-22 | Reiterated | Barclays | Equal Weight |
| Feb-04-22 | Reiterated | BofA Securities | Neutral |
| Feb-04-22 | Reiterated | Cowen | Outperform |
| Feb-04-22 | Reiterated | Morgan Stanley | Overweight |
| Feb-04-22 | Reiterated | Needham | Buy |
| Feb-04-22 | Reiterated | Oppenheimer | Outperform |
| Feb-04-22 | Reiterated | RBC Capital Mkts | Sector Perform |
| Feb-04-22 | Reiterated | Robert W. Baird | Neutral |
| Feb-04-22 | Reiterated | Wedbush | Neutral |
| Feb-04-22 | Reiterated | Wells Fargo | Equal Weight |
| Feb-04-22 | Reiterated | Wolfe Research | Peer Perform |
| Jan-13-22 | Downgrade | Guggenheim | Buy → Neutral |
| Jan-12-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-10-21 | Resumed | Raymond James | Mkt Perform |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Neutral |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Sep-23-21 | Initiated | Needham | Buy |
| Jun-18-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jun-14-21 | Reiterated | Truist | Buy |
| Jun-11-21 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Jun-10-21 | Upgrade | UBS | Neutral → Buy |
| Jun-08-21 | Upgrade | Atlantic Equities | Underweight → Neutral |
| Jun-08-21 | Reiterated | Barclays | Equal Weight |
| Jun-08-21 | Upgrade | Citigroup | Sell → Neutral |
| Jun-08-21 | Reiterated | H.C. Wainwright | Buy |
| Jun-08-21 | Reiterated | Jefferies | Buy |
| Jun-08-21 | Reiterated | Morgan Stanley | Overweight |
| Jun-08-21 | Reiterated | RBC Capital Mkts | Sector Perform |
| Jun-08-21 | Upgrade | Robert W. Baird | Underperform → Neutral |
| Jun-08-21 | Reiterated | Stifel | Buy |
| Jun-08-21 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jun-07-21 | Upgrade | BofA Securities | Underperform → Neutral |
| Jun-07-21 | Upgrade | Cowen | Market Perform → Outperform |
| Jun-07-21 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Feb-05-21 | Downgrade | DZ Bank | Buy → Hold |
| Jan-29-21 | Upgrade | Stifel | Hold → Buy |
| Nov-10-20 | Upgrade | DZ Bank | Hold → Buy |
| Nov-09-20 | Downgrade | Atlantic Equities | Neutral → Underweight |
| Nov-09-20 | Downgrade | BofA Securities | Neutral → Underperform |
| Nov-09-20 | Downgrade | Cowen | Outperform → Market Perform |
| Nov-09-20 | Reiterated | H.C. Wainwright | Buy |
| Nov-04-20 | Upgrade | BofA Securities | Underperform → Neutral |
| Nov-04-20 | Upgrade | Jefferies | Hold → Buy |
| Nov-04-20 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Oct-28-20 | Initiated | UBS | Neutral |
| Jul-27-20 | Upgrade | Morgan Stanley | Underweight → Overweight |
| Jun-22-20 | Downgrade | Barclays | Overweight → Equal Weight |
| Jun-22-20 | Reiterated | RBC Capital Mkts | Sector Perform |
| Jun-09-20 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Apr-23-20 | Downgrade | Citigroup | Neutral → Sell |
| Apr-23-20 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Jan-27-20 | Upgrade | Canaccord Genuity | Hold → Buy |
| Dec-13-19 | Upgrade | Credit Suisse | Underperform → Neutral |
| Dec-02-19 | Downgrade | Robert W. Baird | Neutral → Underperform |
View All
Biogen Inc Stock (BIIB) Latest News
Biogen Inc. $BIIB Stake Raised by B. Metzler seel. Sohn & Co. AG - MarketBeat
Biogen Shares Rally 1.43% on Key Therapeutic Advances and Strategic Expansion as $320M Volume Ranks 320th - AInvest
Biogen Showcases Lupus Pipeline But Investors Will Have To Wait For Data - insights.citeline.com
Western Digital, Adobe, Biogen See High Option Trading Volume - AInvest
Risk vs reward if holding onto Biogen Inc.2025 Analyst Calls & Reliable Trade Execution Plans - Newser
Stock Analysis | Biogen OutlookWeak Technicals Cloud Optimistic Fundamentals - AInvest
Investors Holding Back On Biogen Inc. (NASDAQ:BIIB) - 富途牛牛
Is it too late to sell Biogen Inc.Portfolio Gains Report & Daily Technical Forecast Reports - Newser
Biogen Thematic Pipeline Seminar: Lupus - MarketScreener
Should New Zorevunersen and LEQEMBI Launches Influence Biogen's (BIIB) Rare Disease Growth Strategy? - simplywall.st
Biogen Highlights Multiple Assets and Indications in Lupus - Biogen
Eisai and Biogen to launch new Alzheimer's treatment in the US - medwatch.com
Biogen, Eisai begin rolling FDA submissions for Leqembi injectable for starting dose - Seeking Alpha
These Stocks Are Moving the Most Today: Nvidia, Biogen, NIO, Spirit Aviation, and More - MSN
CW Advisors LLC Buys New Holdings in Biogen Inc. $BIIB - MarketBeat
Caisse DE Depot ET Placement DU Quebec Makes New Investment in Biogen Inc. $BIIB - MarketBeat
Ieq Capital LLC Grows Stock Position in Biogen Inc. $BIIB - MarketBeat
Is Biogen Inc. showing insider buying2025 Key Lessons & Smart Money Movement Alerts - khodrobank.com
Biogen Inc. $BIIB Stock Position Decreased by Canada Pension Plan Investment Board - MarketBeat
Can Biogen Inc. reach all time highs this year2025 Support & Resistance & Consistent Profit Trading Strategies - khodrobank.com
Will Biogen Inc. see short term momentumWeekly Volume Report & Free Reliable Trade Execution Plans - Newser
Biogen Inc. $BIIB Holdings Raised by Trexquant Investment LP - MarketBeat
Landscape Capital Management L.L.C. Takes $329,000 Position in Biogen Inc. $BIIB - MarketBeat
American Century Companies Inc. Cuts Stock Position in Biogen Inc. $BIIB - MarketBeat
BNP Paribas Financial Markets Has $50.11 Million Stock Holdings in Biogen Inc. $BIIB - MarketBeat
The Game-Changing Potential of LEQEMBI® IQLIK™ in Early Alzheimer's Disease Treatment and Its Impact on Biogen and Eisai’s Market Position - AInvest
Visual analytics tools that track Biogen Inc. performanceJuly 2025 Final Week & Verified Technical Signals - Newser
Biogen Participating in the Cantor Global Healthcare Conference - Biogen
Real time breakdown of Biogen Inc. stock performance2025 Big Picture & Technical Buy Zone Confirmation - Newser
Evaluating Biogen Inc. with trendline analysisPrice Action & Reliable Volume Spike Trade Alerts - Newser
How institutional ownership impacts Biogen Inc. stockWeekly Earnings Recap & Low Risk High Win Rate Stock Picks - Newser
Biogen to Participate in Upcoming Healthcare Conferences - Biogen
Biogen Executive Makes a Significant Stock Sale - TipRanks
Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status - Quantisnow
Biogen's Stock Surges 5.60% on Bullish Candlestick Pattern and Elevated Volume Amid Overbought Technical Indicators - AInvest
Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer’s Disease Under Fast Track Status - Placera.se
Eisai, Biogen begin FDA submission for Alzheimer’s autoinjector - Investing.com
First At-Home Injection Option for Alzheimer's: Eisai's LEQEMBI IQLIK Could Transform Treatment Access - Stock Titan
Biogen Jumps 5.6% on Heavy Volume as Technicals Signal Bullish Reversal - AInvest
Can Biogen Inc. sustain its profitabilityWeekly Stock Recap & Growth Oriented Trade Recommendations - خودرو بانک
Biogen Inc. stock outperforms competitors on strong trading day - MarketWatch
Biogen’s Surging Stock: Is a Breakthrough Imminent? - StocksToTrade
Is Biogen Inc. stock undervalued right nowAnalyst Downgrade & Weekly Market Pulse Alerts - خودرو بانک
Biogen (BIIB) Stock Is Up, What You Need To Know - Yahoo Finance
Biogen’s Sudden Surge: A Strategic Insight? - timothysykes.com
Biogen’s Strategic Moves: New Horizons or Risk? - StocksToTrade
Biogen Inc. (BIIB)’s Alzheimer’s Drug Leqembi Wins EU Nod, Now Approved in 48 Countries - MSN
Sector Update: Health Care Stocks Retreat Tuesday Afternoon - MarketScreener
Biogen Inc Stock (BIIB) Financials Data
Revenue
Net Income
Cash Flow
EPS
Biogen Inc Stock (BIIB) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Singhal Priya | Head of Development |
Sep 02 '25 |
Sale |
133.55 |
517 |
69,045 |
5,772 |
9.14%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):